Do analysts prefer CCM or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CCM or BMGL?

Basel Medical Group has lower revenue, but higher earnings than Concord Medical Services. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $65.85M 0.29 -$13.27M N/A N/A Basel Medical Group $11.32M 0.98 -$9.50M N/A N/A

Is CCM or BMGL more profitable?

Company Net Margins Return on Equity Return on Assets Concord Medical Services N/A N/A N/A Basel Medical Group N/A N/A N/A

Does the media prefer CCM or BMGL?

In the previous week, Basel Medical Group had 5 more articles in the media than Concord Medical Services. MarketBeat recorded 8 mentions for Basel Medical Group and 3 mentions for Concord Medical Services. Basel Medical Group's average media sentiment score of 0.23 beat Concord Medical Services' score of 0.22 indicating that Basel Medical Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Concord Medical Services 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Basel Medical Group 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MRAI or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, MRAI or BMGL?

Basel Medical Group has lower revenue, but higher earnings than Marpai. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marpai $34.87M 0.42 -$28.75M -$0.87 N/A Basel Medical Group $11.32M 0.98 -$9.50M N/A N/A

Is MRAI or BMGL more profitable?

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai -85.70% N/A -100.23% Basel Medical Group N/A N/A N/A

Do analysts recommend BRTX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, BRTX or BMGL?

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biorestorative Therapies $360K 24.95 -$14.24M -$1.07 N/A Basel Medical Group $11.32M 0.98 -$9.50M N/A N/A

Do analysts recommend ACON or BMGL?

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 140.38%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Basel Medical Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ACON or BMGL?

Aclarion has higher earnings, but lower revenue than Basel Medical Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclarion $80K 95.94 -$7.23M -$9.03 N/A Basel Medical Group $11.32M 0.98 -$9.50M N/A N/A

Does the media refer more to ACON or BMGL?

In the previous week, Basel Medical Group had 4 more articles in the media than Aclarion. MarketBeat recorded 8 mentions for Basel Medical Group and 4 mentions for Aclarion. Aclarion's average media sentiment score of 0.31 beat Basel Medical Group's score of 0.23 indicating that Aclarion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Basel Medical Group 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MGRX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, MGRX or BMGL?

Basel Medical Group has higher revenue and earnings than Mangoceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mangoceuticals $414.58K 14.77 -$20.64M -$1.49 N/A Basel Medical Group $11.32M 0.98 -$9.50M N/A N/A

Basel Medical Group (BMGL) Competitors

$0.59 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.57 -0.02 (-2.86%)

As of 06/12/2026 06:49 PM Eastern

Compare

BMGL vs. CCM, MRAI, BRTX, ACON, and MGRX

Should you buy Basel Medical Group stock or one of its competitors? MarketBeat compares Basel Medical Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Basel Medical Group include Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), Aclarion (ACON), and Mangoceuticals (MGRX). These companies are all part of the "healthcare" industry.

How does Basel Medical Group compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Basel Medical Group has lower revenue, but higher earnings than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.29	-$13.27M	N/A	N/A
Basel Medical Group	$11.32M	0.98	-$9.50M	N/A	N/A

In the previous week, Basel Medical Group had 5 more articles in the media than Concord Medical Services. MarketBeat recorded 8 mentions for Basel Medical Group and 3 mentions for Concord Medical Services. Basel Medical Group's average media sentiment score of 0.23 beat Concord Medical Services' score of 0.22 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Concord Medical Services	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Basel Medical Group	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Basel Medical Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Concord Medical Services has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

Basel Medical Group beats Concord Medical Services on 5 of the 6 factors compared between the two stocks.

How does Basel Medical Group compare to Marpai?

Marpai (NASDAQ:MRAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
Basel Medical Group	N/A	N/A	N/A

Marpai has a beta of 4.94, meaning that its share price is 394% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Basel Medical Group has lower revenue, but higher earnings than Marpai.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.42	-$28.75M	-$0.87	N/A
Basel Medical Group	$11.32M	0.98	-$9.50M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Basel Medical Group had 8 more articles in the media than Marpai. MarketBeat recorded 8 mentions for Basel Medical Group and 0 mentions for Marpai. Basel Medical Group's average media sentiment score of 0.23 beat Marpai's score of 0.00 indicating that Basel Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Marpai	Neutral
Basel Medical Group	Neutral

Summary

Basel Medical Group beats Marpai on 7 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Basel Medical Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Basel Medical Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Basel Medical Group	N/A	N/A	N/A

Biorestorative Therapies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	24.95	-$14.24M	-$1.07	N/A
Basel Medical Group	$11.32M	0.98	-$9.50M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.4% of Biorestorative Therapies shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Basel Medical Group had 6 more articles in the media than Biorestorative Therapies. MarketBeat recorded 8 mentions for Basel Medical Group and 2 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.44 beat Basel Medical Group's score of 0.23 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Basel Medical Group	Neutral

Summary

Basel Medical Group beats Biorestorative Therapies on 6 of the 11 factors compared between the two stocks.

How does Basel Medical Group compare to Aclarion?

Aclarion (NASDAQ:ACON) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Basel Medical Group had 4 more articles in the media than Aclarion. MarketBeat recorded 8 mentions for Basel Medical Group and 4 mentions for Aclarion. Aclarion's average media sentiment score of 0.31 beat Basel Medical Group's score of 0.23 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Basel Medical Group	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Basel Medical Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-54.41%	-51.71%
Basel Medical Group	N/A	N/A	N/A

Aclarion presently has a consensus price target of $7.50, indicating a potential upside of 140.38%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Basel Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aclarion has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Aclarion has higher earnings, but lower revenue than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	95.94	-$7.23M	-$9.03	N/A
Basel Medical Group	$11.32M	0.98	-$9.50M	N/A	N/A

Summary

Aclarion beats Basel Medical Group on 9 of the 14 factors compared between the two stocks.

How does Basel Medical Group compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Mangoceuticals has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Basel Medical Group had 6 more articles in the media than Mangoceuticals. MarketBeat recorded 8 mentions for Basel Medical Group and 2 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 1.43 beat Basel Medical Group's score of 0.23 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Mangoceuticals	Positive
Basel Medical Group	Neutral

Basel Medical Group has higher revenue and earnings than Mangoceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$414.58K	14.77	-$20.64M	-$1.49	N/A
Basel Medical Group	$11.32M	0.98	-$9.50M	N/A	N/A

Basel Medical Group has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,639.13%. Basel Medical Group's return on equity of 0.00% beat Mangoceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,639.13%	-112.00%	-104.96%
Basel Medical Group	N/A	N/A	N/A

Summary

Basel Medical Group beats Mangoceuticals on 6 of the 11 factors compared between the two stocks.

Get Basel Medical Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMGL vs. The Competition

Export

Metric	Basel Medical Group	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.08M	$8.90B	$6.52B	$12.05B
Dividend Yield	N/A	1.71%	2.67%	5.66%
P/E Ratio	N/A	24.23	24.00	24.42
Price / Sales	0.98	23.90	515.84	118.72
Price / Cash	N/A	13.73	27.48	37.92
Price / Book	2.95	5.53	10.60	6.82
Net Income	-$9.50M	$177.22M	$3.57B	$337.56M
7 Day Performance	-0.79%	1.54%	0.59%	1.16%
1 Month Performance	-10.10%	10.04%	1.54%	3.16%
1 Year Performance	-82.95%	5.88%	25.41%	30.60%

Basel Medical Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMGL Basel Medical Group	0.7243 of 5 stars	$0.59 flat	N/A	-83.0%	$11.08M	$11.32M	N/A	36	Gap Down
CCM Concord Medical Services	0.5092 of 5 stars	$4.74 -6.4%	N/A	-32.8%	$20.75M	$65.85M	N/A	970	Gap Up
MRAI Marpai	N/A	$0.57 +1.8%	N/A	-59.0%	$14.57M	$34.87M	N/A	150	Gap Down
BRTX Biorestorative Therapies	0.5576 of 5 stars	$0.41 -2.2%	N/A	-79.0%	$10.32M	$360K	N/A	7
ACON Aclarion	3.6532 of 5 stars	$3.57 +1.1%	$7.50 +110.1%	-58.1%	$8.79M	$80K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMGL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Basel Medical Group (BMGL) Competitors

BMGL vs. CCM, MRAI, BRTX, ACON, and MGRX

How does Basel Medical Group compare to Concord Medical Services?

Summary

How does Basel Medical Group compare to Marpai?

Summary

How does Basel Medical Group compare to Biorestorative Therapies?

Summary

How does Basel Medical Group compare to Aclarion?

Summary

How does Basel Medical Group compare to Mangoceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Basel Medical Group (BMGL) Competitors

BMGL vs. CCM, MRAI, BRTX, ACON, and MGRX

How does Basel Medical Group compare to Concord Medical Services?

Which has better valuation and earnings, CCM or BMGL?

Does the media prefer CCM or BMGL?

Is CCM or BMGL more profitable?

Do analysts prefer CCM or BMGL?

Which has more volatility and risk, CCM or BMGL?

Summary

How does Basel Medical Group compare to Marpai?

Is MRAI or BMGL more profitable?

Which has more risk and volatility, MRAI or BMGL?

Which has higher earnings and valuation, MRAI or BMGL?

Do analysts recommend MRAI or BMGL?

Do insiders and institutionals hold more shares of MRAI or BMGL?

Does the media refer more to MRAI or BMGL?

Summary

How does Basel Medical Group compare to Biorestorative Therapies?

Is BRTX or BMGL more profitable?

Which has more risk and volatility, BRTX or BMGL?

Which has higher earnings and valuation, BRTX or BMGL?

Do analysts recommend BRTX or BMGL?

Do insiders and institutionals hold more shares of BRTX or BMGL?

Does the media refer more to BRTX or BMGL?

Summary

How does Basel Medical Group compare to Aclarion?

Does the media refer more to ACON or BMGL?

Do institutionals and insiders believe in ACON or BMGL?

Is ACON or BMGL more profitable?

Do analysts recommend ACON or BMGL?

Which has more risk & volatility, ACON or BMGL?

Which has preferable earnings and valuation, ACON or BMGL?

Summary

How does Basel Medical Group compare to Mangoceuticals?

Which has more volatility & risk, MGRX or BMGL?

Do analysts recommend MGRX or BMGL?

Do institutionals and insiders hold more shares of MGRX or BMGL?

Does the media refer more to MGRX or BMGL?

Which has stronger earnings & valuation, MGRX or BMGL?

Is MGRX or BMGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL vs. The Competition

Basel Medical Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools